Trial Profile
A Sourcing Study to Collect Human Biological (Serum) Samples From Healthy Adults
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal group B infections; Meningococcal infections
- Focus Pharmacodynamics
- Acronyms MENB REC 2ND GEN-079 HBS
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 24 Jun 2022 Status changed from active, no longer recruiting to completed.
- 19 Oct 2021 Planned End Date changed from 22 Sep 2023 to 30 Jun 2022.
- 19 Oct 2021 Planned primary completion date changed from 22 Sep 2023 to 30 Jun 2022.